ARGX
ARGX
Positions held
Your positionsARGX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · ARGX Stock Sinks as Argenx Scraps Late-Stage Trial
2026-10-08 · Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
2026-10-08 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-10-08 · Sector Update: Healthcare Stocks Decline in Afternoon Trading
2026-10-08 · IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
2026-10-08 · Argenx Stock Sinks on Scrapped Autoimmune Drug Trial. Why the Selloff Is Overdone.
2026-10-08 · HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
2026-10-08 · argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
2026-10-08 · Argenx falls as Sjögren’s setback offsets celiac drug progress
2026-10-08 · European Equities Traded in US as ADRs Fall in Thursday Trading
2026-10-08 · argenx Reports Positive Phase 2 Celiac Disease Trial Results, Plans Phase 3 Development of FB102
2026-10-08 · Argenx Sinks 11% as Sjogren’s Trial Halted for Futility: “Disappointed by This Outcome”
Price (daily)
Full chart · RSI · MACD · patterns